Weiss Law reminds shareholders of MNRL, ECOM, SBTX and IRBT of its ongoing investigations

NEW YORK, September 29, 2022 /PRNewswire/ —

If you hold shares in any of the companies listed above and
want to discuss our surveys or have questions about
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
Weiss’ law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Brigham Minerals, Inc. (NYSE: MNRL)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Brigham Minerals, Inc. (NYSE: MNRL), as part of its proposed merger with Sitio Royalties Corp. (“Sitio”). Under the terms of the merger agreement, MNRL shareholders will receive a fixed exchange ratio of 1.133 common shares of the combined company for each MNRL common share held, and Sitio shareholders will receive one common share of the combined company for each Sitio ordinary share held. Upon completion of the transaction, Sitio shareholders will own approximately 54.0% and MNRL shareholders will only own approximately 46.0% of the combined company. If you own MNRL stock and would like to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/mnrl

ChannelAdvisor Corporation (NYSE: ECOM)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of ChannelAdvisor Corporation (NYSE: ECOM) as part of CommerceHub’s proposed acquisition of ECOM. Under the terms of the merger agreement, ECOM shareholders will receive $23.10 in cash for each ordinary share held by ECOM. If you own ECOM stock and would like to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/ecom

Silverback Therapeutics, Inc. (NASDAQ: SBTX)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Silverback Therapeutics, Inc. (NASDAQ: SBTX), in connection with SBTX’s proposed merger with ARS Pharmaceuticals, Inc. (“ARS”). Under the terms of the merger agreement, assuming SBTX’s net cash at closing is $240 million, SBTX shareholders are expected to own approximately 37% of the combined company and ARS shareholders prior to the merger are expected to own approximately 63% of the combined company. If you own SBTX stock and would like to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/sbtx

iRobot Corporation (NASDAQ:IRBT)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of iRobot Corporation (NASDAQ:IRBT) as part of the planned acquisition of IRBT by Amazon.co.ukInc. Under the terms of the merger agreement, IRBT shareholders will receive $61.00 in cash for each common share of IRBT held. If you hold IRBT shares and would like to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/irbt

SOURCE Weiss’ Law

Comments are closed.